| Antagonist activity at cynomolgus monkey CCR5 expressed in CHO cells assessed as MIP-1-alpha-induced Ca2+ mobilization - BioAssay Summary Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the identification of NIBR-1282 which did not show adverse effects when tested in an isolated rabbit heart ex vivo model. Administration of NIBR-1282 in combination with a non-efficacious dose of CsA led to significant prolongation of kidney allograft survival in cynomolgus monkeys. ..more |
_ | |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target BioActive Compound: 1 Description: Title: Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Abstract: Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the identification of NIBR-1282 which did not show adverse effects when tested in an isolated rabbit heart ex vivo model. Administration of NIBR-1282 in combination with a non-efficacious dose of CsA led to significant prolongation of kidney allograft survival in cynomolgus monkeys. (PMID: 18267361) Comment Compounds with activity <= 50uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation. Categorized Comment ChEMBL Assay Type: Functional ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 102807 ChEMBL target type: Target is a single protein chain Result Definitions
* Activity Concentration. Data Table (Concise)
PageFrom: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||